Myocardial Remodeling.- Ventricular Remodeling In Ischemic Cardiomyopathy.- Myocardial Regeneration.- Myocardial Regeneration: Which Cell and Why.- Cardiac Stem Cells.- Cardiac Stem Cells for Myocardial Regeneration.- Skeletal Myoblast.- A Historic Recapitulation of Myoblast Transplantation.- Myoblast Cell Transplantation: Preclinical Studies.- Skeletal Myoblasts: The European Experience.- Skeletal Myoblasts: The U.S. Experience.- Progenitor Cells.- Progenitor Cells for Cardiac Regeneration.- Bone Marrow.- Bone Marrow-Derived Stem Cell for Myocardial Regeneration: Preclinical Experience.- Bone Marrow Derived Stem Cells for Myocardial Regeneration: Clinical Experience, Surgical Delivery.- Autologous Mononuclear Bone Marrow Cell Transplantion for Myocardial Infarction: The German Experience.- Autologous Mononuclear Bone Marrow Transplantation for Myocardial Infarction: The Spanish Experience.- Mobilizing Bone Marrow Stem Cells for Myocardial Repair After Acute Myocardial Infarction.- Percutaneous Stem Cell Transplantation.- Percutaneous Myoblast Transplantation: Steps In Translational Research.- A Porcine Model of Myocardial Infarction for Evaluation of Cell Transplantation.- Tissue Engineering.- Tissue Engineering for Myocardial Regeneration.- Functional and Electrophysiological Assessment after Cell Tranplantation.- The Role of Pet Scan in Stem Cell Therapy.- The Measurement of Systolic Function in the Mammalian Heart.- Electrophysiological Aspects of Cell Transplantation.- Regulatory Perspective.- Regulatory Considerations in Manufacturing, Product Testing, and Preclinical Development of Cellular Products for Cardiac Repair.
In excess of 7 million people worldwide die of coronary heart disease each year. Only one-third of these heart attack victims recover completely. The remainder suffer the consequences of myocardial infarction and its ill fated remodeling process, resulting in chronic congestive heart failure. This malady alone is the leading cause of hospital admissions in the United States.
New breakthroughs in stem cell therapy and tissue engineering have promised to reverse this dismal outcome by cardiovascular repair. World authorities, including scientists and regulatory authorities, have joined in a collaborative effort to present for the reader the first collective review of stem cell therapy for the treatment of cardiovascular disease. These contributions in basic science, pre-clinical and clinical experience guided by the regulatory pathways, assure a rapid course of translational research and clinical trials.
The contents of this publication will become a prerequisite for those preparing to meet the challenges of this exciting and potentially rewarding field of stem cell research.
World authorities, including scientists and regulatory authorities, have joined in a collaborative effort to present for the reader the first collective review of stem cell therapy for the treatment of cardiovascular disease